

FOI 3343

15th October 2025

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

How many new patients were treated for Psoriasis by the Trust's Dermatology Department in the latest 3-month period of June, July and August (or the latest 3 months available) with the treatments I have provided below?

Response:

Information not held

Please can you define a "new patient" as a patient who has received any of the treatments listed below for the first time. If a patient received any of the below treatments before the 1st of June 2025, they can be classed as a new patient for the purposes of this question.

Current patients as of 25/09/2025

- Adalimumab [Humira] - 8
- Adalimumab [All Biosimilars] - 248
- Etanercept [Enbrel] - 0
- Etanercept [All Biosimilars] - <5
- Infliximab [Remicade] - 0
- Infliximab [All Biosimilars] - <5
- Ustekinumab [Stelara] - <5
- Ustekinumab [All Biosimilars] - 20
- Apremilast [Otezla] - 0
- Bimekizumab [Bimzelx] - 14
- Brodalumab [Kyntheum] - 5
- Certolizumab [Cimzia] - <5
- Deucravacitinib [Sotyktu] - 0
- Dimethyl Fumarate [Skilarence] - 0
- Guselkumab [Tremfya] - 69
- Ixekizumab [Taltz] - 123
- Risankizumab [Skyrizi] - 108
- Secukinumab [Cosentyx] - 31
- Spesolimab [Spevigo] - 0
- Tildrakizumab [illumetri] - 5

The Trust has a legal duty to protect patient confidentiality and, in line with this duty, the figure <5 has been provided where figures are very low. This is because of the potential

risk of identification of an individual. In reaching this decision the Trust has taken into account the small geographical area which the Trust serves and the sensitivity of the information requested. In addition the Trust has taken into account the fact that all information disclosed in response to an FOI is disclosed to the 'world at large' and is published on the Trust website.

S 40 (2) (third party information) of the Freedom of Information Act 2000 has been applied to exempt the redacted information from disclosure. The Trust does not consider the disclosure of the redacted information to be fair to the individuals concerned as there is the potential risk of identification of an individual(s) which they would not expect, and which would therefore breach the fairness element of the first principle of the Data Protection Act 2018.

Email: Foi.Team@Southerntrust.hscni.net